Loading
A phase 2/3 trial testing Navlimetostat in non-small-cell lung cancer, now recruiting.
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion is a phase 2/3 interventional study registered as NCT07063745, led by Bristol-Myers Squibb, and recruiting on the registry. Official title: A Randomised Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion. Planned enrolment is 590 participants (estimated). The study started in 2026-01-02 and primary completion is expected in 2031-08-12. No results have been posted on ClinicalTrials.gov.
Shares Navlimetostat, Bristol Myers Squibb.